DLBCL

The agent, EZM0414, will be explored in DLBCL, multiple myeloma, and non-multiple myeloma after the completion of a phase 1 dose-finding study.

The efficacy and data for the combination of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma show effective outcomes for patients that clinicians can use when discussing treatment options.

Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old patient with diffuse large B-cell lymphoma presented with fever, drenching night sweats, and recurrent back pain.

Looking at the combination of lenalidomide plus tafasitamab for patients with diffuse large B-cell lymphoma shows promise for patients' treatment, but challenges remain that clinicians need to address.

Jason Westin, MD, discusses the future of diffuse large B-cell lymphoma treatment.

During a live virtual event with other physicians, Bijal Shah, MD, MS, discussed treatment options for patients with diffuse large B-cell lymphoma and the data that backs up the efficacy for these options.

75-year-old man presented with fever, a 7-lb unintentional weight loss, and occasional chest pain.

In an interview with Targeted Oncology, Jason Westin, MD, discussed the future of DLBCL treatment in both the frontline and later-line settings, along with current unmet clinical needs.

Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old woman with diffuse large B-cell lymphoma complained of fever, night sweats, and back pain.

Jason Westin, MD, discusses the current standard of care in diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Brad S. Kahl, MD, provided an efficacy update from the LOTUS-2 study and discussed multiple agents showing promise for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Encouraging results have been reported from the phase 2 Guidance-01 clinical trial.

Mehdi Hamadani, MD and Bertram Glass, MD recently debated on the role of allogeneic hematopoietic stem cell transplant for the treatment of aggressive B-cell lymphoma now that chimeric antigen receptor T cells have entered the landscape.

During a Targeted Oncology Case-Based Roundtable event, John M. Burke, MD, discussed the challenges with treating relapsed or refractory diffuse large B-cell lymphoma with a group of peers.

Expert insight on the GO29365 trial, which informs selection of polatuzumab + bendamustine and rituximab in patients with relapsed/refractory DLBCL.

Daniel O. Persky, MD, reflects on a patient’s relapse with diffuse large B-cell lymphoma and the rationale behind treatment with polatuzumab + BR.

A review of frontline treatment options for DLBCL informed by comprehensive patient workup and the efficacy of available therapies.

Expert hematologist/oncologist Daniel O. Persky, MD, reviews the case of a 73-year-old woman who is diagnosed with and treated for DLBCL, later to relapse and require novel therapy.

Christopher R. Flowers, MD, discusses the current therapies used for patients with relapsed/refractory diffuse large B-cell lymphoma and goes into specifics of the L-MIND trial after the long-term follow-up.

Grzegorz S. Nowakowski, MD and Stephen D. Smith lead other participants of a Case Based Roundtable event in a discussion around treatment for patients with transplant-ineligible diffuse large B-cell lymphoma.

One year after being diagnosed with CD-10- positive and CD10-positive diffuse large B-cell lymphoma being treated with R-CHOP, and achieving complete remission, a PET/CT scan confirmed relapse in a 74-year-old male patient.

A significantly improved and clinically meaningful progression-free survival was accomplished by combining polatuzumab vedotin and R-CHOP in patients with previously untreated diffuse large B-cell lymphoma compared with R-CHOP alone, according to results of the phase 3 POLARIX trial.

The laboratory results, lymph node biopsy, imaging studies and other information of a 75-year-old patient with diffuse large B-cell lymphoma were brought into consideration during a Targeted Oncology Case-Based Roundtable discussion around treatment with tafasitamab and lenalidomide (Revlimid).

Gilles Salles, MD, discusses the need for new therapies to treat diffuse large B-cell lymphoma.

Matthew A. Lunning, DO began a Case-Based Roundtable event by asking a group of oncologists how diffuse large b-cell lymphoma in handling in their practices. The responses varied, considering some of the oncologists worked in academic centers and some worked in the community setting.

Laurie Sehn, MD, discusses the unmet needs and future directions in the treatment of relapsed/refractory diffuse large B-cell lymphoma.

A key opinion leader reviews novel therapies for diffuse large B-cell lymphoma.

Dr Laurie Sehn reviews the NCCN guidelines for second-line therapy in relapsed/refractory diffuse large B-cell lymphoma and discusses the clinical trial data for a recently approved new treatment combination.

An expert hematologist-oncologist describes risk assessment for diffuse large B-cell lymphoma, as well as first-line therapy selection based on risk and other factors.

Laurie Sehn, MD, presents the case of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma.